New contrast agent could mean lower doses for heart MRI

NCT ID NCT05954559

Recruiting now Diagnosis Sponsor: Johns Hopkins University Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a new MRI contrast agent called Elucirem can detect heart scarring as effectively as the standard agent, but at a much lower dose. Researchers will compare images from 25 adults who previously had a heart MRI with the standard agent. If Elucirem works well at half the usual dose, it could mean less contrast agent exposure for patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Elucirem (Gadopiclenol)
What this could lead to: If successful, this could allow doctors to use a lower dose of contrast agent for heart MRI, potentially reducing risks while still accurately detecting heart scarring.
What could go wrong: This is a very small, early-phase study with only 25 participants. The new agent may not perform as well as the standard one at lower doses, and results may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MYOCARDIAL FIBROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endomyocardial fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MYOCARDIAL FIBROSIS

Contacts and locations

Locations

Johns Hopkins Center for Advanced Imaging and Research Science, located in the Science + Technology Park at 1812 Ashland Avenue, Baltimore, MD.
RECRUITING

Baltimore, Maryland, 21202, United States
Johns Hopkins School of Medicine
NOT_YET_RECRUITING

Baltimore, Maryland, 21205, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.